Solubest’s technology enhances the solubility of drugs that combat AIDS-related and various other fungal infections.
Israeli start-up Solubest has raised $1.4 million from its previous investor, Alplex BV, the BioIsrael website reported last week. The money is slated use nanotechnology for development of active materials to treat various infectious diseases.
Solubest’s technology enhances the solubility of drugs that combat AIDS-related and various other fungal infections. Greater solubility of the material in the stomach and the bloodstream is designed to make the material more effective, making it possible to reduce dosages and curb side effects. Development of new drug delivery methods, which have been registered as patents, can also extend the patent period for each drug.
Chairman, and CEO Erwin Stern founded Rehovot-based Solubest in 2001. Solubest is a member of the Israeli Nanoparticles consortium. The company says it has signed agreements concerning its technology with major pharmaceutical firms in the US, Israel, and Europe.
Published by Globes [online] - www.globes.co.il - on February 9, 2003